Results 11 to 20 of about 3,619 (165)

Case report: Acamprosate for treatment of volatile hydrocarbon (VHC) inhalant use disorder with comorbid alcohol use disorder [PDF]

Mental Health Clinician
Introduction Inhalant use disorder is a substance use disorder that involves the inhalation of volatile hydrocarbons (VHCs) to experience intoxication.
Nariman Piri, PharmD, BCPP, Wesley Campbell, PharmD, BCPP, BCPS   +1 more
doaj   +2 more sources

Review of acamprosate pharmacokinetics and dosing strategies [PDF]

Mental Health Clinician
Introduction: Alcohol use disorder (AUD) is associated with significant morbidity and mortality, contributing to 5% of annual deaths. Although some literature suggests that acamprosate is an effective treatment for AUD, its traditional dosing regimen of ...
Lauren Steil, PharmD, Dale Terasaki, MD, MPH, Rebecca Reiss, PharmD, BCPP, Michael Deaney, PharmD, AAHIVP   +3 more
doaj   +2 more sources

Addiction-related problems in Japan: A regional perspective. [PDF]

Addiction
Abstract Japan's addiction landscape appears paradoxical. The lifetime use of illicit drugs is among the lowest in Organisation for Economic Cooperation and Development countries, but harm from alcohol, tobacco, and gambling ranks among the world's highest.
Ide S, Nishitani Y, Sumitani M, Minami M, Isa T, Iseki M, Ohkura M, Okamoto H, Kikuchi T, Sekino Y, Takahashi H, Takeuchi K, Nitta A, Honjo T, Matsumoto H, Miyakawa T, Murai T, Matsumoto T, Nakagome K, Ikeda K.   +19 more
europepmc   +2 more sources

Real-world analysis of acamprosate use in patients with cirrhosis and alcohol-associated hepatitis [PDF]

BMJ Open Gastroenterology
Objective Preventing return to alcohol is of critical importance for patients with alcohol-related cirrhosis and/or alcohol-associated hepatitis. Acamprosate is a widely used treatment for alcohol use disorder (AUD). We assessed the impact of acamprosate
Christopher Oldroyd, Michael Allison, Jonathan Wood   +2 more
doaj   +2 more sources

GLP-1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review. [PDF]

Alcohol Clin Exp Res (Hoboken)
This narrative review of the development of GLP‐1 receptor agonists provides a foundation for both preclinical and clinical research on their use for treating alcohol use disorder (AUD). Both observational studies using real‐world data and randomized controlled clinical trials support the potential utility of these medications for treating AUD ...
Woo S, Zhu G, Castro C, Phuong A, Roy A, Davis CN, Kranzler HR.   +6 more
europepmc   +2 more sources

The effects of sub-chronic calcium treatment on ethanol-induced dopamine elevation and the alcohol deprivation effect in the rat [PDF]

Translational Psychiatry
Alcohol use disorder (AUD) is a serious mental health condition and a risk factor for morbidity and preterm death. The drug acamprosate (Campral® – calcium-bis[N-acetylhomotaurinate]) is one of few pharmacological treatments available for AUD.
Karin Ademar, Klara Danielsson, Bo Söderpalm, Louise Adermark, Mia Ericson   +4 more
doaj   +2 more sources

Acamprosate for alcohol dependence [PDF]

São Paulo Medical Journal, 2010
BACKGROUND: Alcohol dependence is among the main leading health risk factors in most developed and developing countries. Therapeutic success of psychosocial programs for relapse prevention is moderate, but could potentially be increased by an adjuvant ...
Susanne Rösner, Andrea Hackl-Herrwerth, Stefan Leucht, Philippe Lehert, Simona Vecchi, Michael Soyka   +5 more
doaj   +4 more sources

A comparative study evaluating the efficacy of naltrexone versus acamprosate as anticraving agents in alcohol use disorder

Industrial Psychiatry Journal
Background: Alcohol use disorders (AUDs) are characterized by excessive alcohol consumption, negatively impacting health, social life, and economic status. Globally, AUD contributes to significant disease burden, causing millions deaths annually. Despite
Samant Singh, Lakhan Kataria, Mohd Rashid Alam   +2 more
doaj   +2 more sources

Low dose baclofen and standard dose acamprosate had comparable changes in brain glutamate, brain Gamma amino butyric acid (GABA) and craving among patients with alcohol dependence syndrome: A 1H-MRS based open label randomized study

Industrial Psychiatry Journal
Background: Understanding of the mechanism of action of Baclofen as anticraving inalcohol dependence syndrome (ADS) is limited. Aim: Our study aimed to examine and compareearly changes in brain glutamate and GABA with Baclofen and Acamprosate among ...
Akhil Kesan, Pranjal Dey, Sourav Khanra, Samiksha Singhai, Monalisa Boro   +4 more
doaj   +2 more sources

Contingency management interventions for substance use and addictive behaviours: Review of the United Kingdom evidence base. [PDF]

Addiction
Abstract Background and aims Substance use and other addictive behaviours including gambling remain major public health concerns in the UK. Despite the effectiveness of substance use treatment approaches, treatment adherence and success rates remain low.
Getty CA, McQuarrie T, Brobbin E.
europepmc   +2 more sources